Cargando…

Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan

The purpose of this trial was to evaluate the efficacy of 2-year consolidation therapy with nilotinib, at a dose of 300 mg twice daily, for achieving treatment-free remission in chronic myeloid leukemia patients with a deep molecular response (BCR-ABL1(IS) ≤0.0032%). Successful treatment-free remiss...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takahashi, Naoto, Nishiwaki, Kaichi, Nakaseko, Chiaki, Aotsuka, Nobuyuki, Sano, Koji, Ohwada, Chikako, Kuroki, Jun, Kimura, Hideo, Tokuhira, Michihide, Mitani, Kinuko, Fujikawa, Kazuhisa, Iwase, Osamu, Ohishi, Kohshi, Kimura, Fumihiko, Fukuda, Tetsuya, Tanosaki, Sakae, Takahashi, Saori, Kameoka, Yoshihiro, Nishikawa, Hiroyoshi, Wakita, Hisashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278957/ https://www.ncbi.nlm.nih.gov/pubmed/29976734 http://dx.doi.org/10.3324/haematol.2018.194894

Ejemplares similares

Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response
por: Okamoto, Yuji, et al.
Publicado: (2022)

Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic‐phase chronic myeloid leukemia based on early achievement of deep molecular response (MR(4.5)): The phase 2, multicenter N‐Road study
por: Nishiwaki, Kaichi, et al.
Publicado: (2020)

Detection of MYD88 L265P mutation by next-generation deep sequencing in peripheral blood mononuclear cells of Waldenström’s macroglobulinemia and IgM monoclonal gammopathy of undetermined significance
por: Nakamura, Ayako, et al.
Publicado: (2019)

Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib
por: Takahashi, Naoto, et al.
Publicado: (2014)

The clinical impact of absolute lymphocyte count in peripheral blood among patients with methotrexate - associated lymphoproliferative disorders
por: Tokuhira, Michihide, et al.
Publicado: (2020)

Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation
por: Kumagai, Takashi, et al.
Publicado: (2017)

Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment‐free remission
por: Kumagai, Takashi, et al.
Publicado: (2020)

Syndrome of Inappropriate Antidiuretic Hormone Secretion in a Patient with Mucosa-associated Lymphoid Tissue Lymphoma
por: Shimizu, Naomi, et al.
Publicado: (2017)

Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders
por: Tokuhira, Michihide, et al.
Publicado: (2019)

Extramedullary blast crisis of chronic myelogenous leukemia as an initial presentation()
por: Tsukamoto, Shokichi, et al.
Publicado: (2013)

Budget impact analysis of treatment‐free remission in nilotinib‐treated Japanese chronic myeloid leukemia patients
por: Yamazaki, Kiyotaka, et al.
Publicado: (2020)

TM-233, a novel analog of 1′-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities
por: Sagawa, Morihiko, et al.
Publicado: (2015)

Nilotinib-Associated Destructive Thyroiditis
por: Bakerywala, Suhalia, et al.
Publicado: (2015)

Nilotinib-Induced Keratosis Pilaris
por: Leong, Wai Mun Sean, et al.
Publicado: (2016)

Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
por: Na, Yoo Jin, et al.
Publicado: (2021)

Drug interaction between tacrolimus and nilotinib in a patient with chronic myeloid leukemia after renal transplant
por: Onaka, Takashi, et al.
Publicado: (2017)

Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy
por: Abumiya, Maiko, et al.
Publicado: (2021)

The Successful Treatment of a Cord Blood Transplant Recipient with Varicella Zoster Virus Meningitis, Radiculitis and Myelitis with Foscarnet
por: Shimizu, Ryo, et al.
Publicado: (2017)

Nilotinib based pharmacophore models for BCRABL
por: Sabitha, Kesavan
Publicado: (2012)

Nilotinib – Differentiating the Hope from the Hype
por: Wyse, Richard K., et al.
Publicado: (2016)

Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study
por: Hochhaus, Andreas, et al.
Publicado: (2015)

S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.
por: Hochhaus, Andreas, et al.
Publicado: (2023)

Reactivation of Hepatitis B Virus in Hematopoietic Stem Cell Transplant Recipients in Japan: Efficacy of Nucleos(t)ide Analogues for Prevention and Treatment
por: Nakamoto, Shingo, et al.
Publicado: (2014)

Rapid deterioration of intravascular large B-cell lymphoma with mass formation in the trigeminal nerve and multiple organ infiltration: An autopsy case report
por: Tanaka, Yuka, et al.
Publicado: (2021)

Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells
por: Tanaka, Atsushi, et al.
Publicado: (2019)

Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple Myeloma
por: Suzuki, Kazuhito, et al.
Publicado: (2021)

Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity
por: Suzuki, Kazuhito, et al.
Publicado: (2021)

Effects of nilotinib on regulatory T cells: the dose matters
por: Fei, Fei, et al.
Publicado: (2010)

Nilotinib-induced Perforating Folliculitis: Two Cases
por: Saraswat, Neerja, et al.
Publicado: (2018)

Nilotinib: QTc prolongation: 2 case reports
Publicado: (2021)

Combination therapeutics of Nilotinib and radiation in acute lymphoblastic leukemia as an effective method against drug-resistance
por: Kaveh, Kamran, et al.
Publicado: (2017)

Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib
por: Boons, Christel C. L. M., et al.
Publicado: (2020)

Successful Treatment of Rapidly Progressive Life-Threatening Esophageal Submucosal Hematoma in a Patient With van der Hoeve Syndrome
por: Watanabe, Yasuhiro, et al.
Publicado: (2018)

Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia
por: Mita, Akiko, et al.
Publicado: (2018)

Surgical resection of recurrent gastrointestinal stromal tumor after interruption of long-term nilotinib therapy
por: Sugase, Takahito, et al.
Publicado: (2016)

Myeloid/Lymphoid Neoplasm with PDGFRB Rearrangement with t(5;10)(q33;q22) Harboring a Novel Breakpoint of the CCDC6-PDGFRB Fusion Gene
por: Yamazaki, Miki, et al.
Publicado: (2019)

Antitumor Effect of the Tyrosine Kinase Inhibitor Nilotinib on Gastrointestinal Stromal Tumor (GIST) and Imatinib-Resistant GIST Cells
por: Sako, Hiroyuki, et al.
Publicado: (2014)

Development and targeted use of nilotinib in chronic myeloid leukemia
por: Fava, Carmen, et al.
Publicado: (2009)

Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
por: Pagan, Fernando, et al.
Publicado: (2016)

Hepatitis B Virus Reactivation under Treatment with Nilotinib
por: Temel, Tuncer, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_dbo2ah3m5t7lr368n280lpbkms